A brief guide to the use of erdafitinib

Erdafitinib (English generic name Erdafitinib, trade name Balversa), as a targeted therapy drug for cancer patients carrying FGFR gene mutations, its correct use is crucial to ensure efficacy and safety. The following is a concise guide to the use of erdafitinib for patient reference.

1. Preparation before taking medicine

1. Confirm gene mutation: Before using erdafitinib, patients need to confirm the presence of FGFR2 or FGFR3 gene mutation or fusion through genetic testing.

2. Doctor's guidance: Follow the doctor's detailed medication instructions, including dosage, medication time, etc.

2. Usage and dosage

1. Starting dose: The usually recommended starting dose is 8mg (two 4mg tablets) daily, taken orally on an empty stomach or with food.

2. Dose adjustment: Based on patient tolerance, the dose may be increased to 9 mg (three 3 mg tablets) daily after evaluation on days 14 to 21.

3. Medication time: Take it at a fixed time every day to keep the drug concentration stable.

3. Precautions

1. Monitor adverse reactions: Erdafitinib may cause a series of adverse reactions, such as stomatitis, fatigue, diarrhea, etc. Patients should undergo regular blood tests, kidney function tests, etc. to monitor drug effects and side effects.

2. Avoid drug interactions: Inform your doctor of all medications you are taking, including prescription drugs, over-the-counter drugs, vitamins, and herbal supplements, to avoid drug-drug interactions.

3. Lifestyle adjustments: Avoid overexposure to the sun, use sunscreen and wear protective clothing. Also, avoid drinking alcohol and smoking to reduce the risk of side effects.

4. Handling special situations

1. Treatment of missed doses: If you miss a dose, you can take it according to the amount within the same day, but the next dose should still be taken according to the original interval.

2. Vomiting treatment: If vomiting occurs after taking medication, it is not recommended to take additional doses. The next dose should still be taken as originally planned.

In conclusion, erdafitinib, as an effective anticancer drug, provides patients with a new treatment option. However, correct use and strict monitoring are key to ensuring efficacy and safety. Patients should strictly follow the doctor's instructions, pay attention to medication details, and report any discomfort in a timely manner so that the doctor can make necessary adjustments. Currently, there are both original versions of erdafitinib available, and more affordable generic drug options are also available on the market. Patients are advised to make a choice based on their personal circumstances.